Apricus Biosciences Inc.

Company Website

11975 El Camino Real Ste., 300
San Diego, CA 92130

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Apricus Biosciences Inc.

Market Cap as of 07/02/2013

$84,047,623

Market Cap as of 06/26/2012

$87,021,790

Market Cap as of 01/04/2012

$107,333,600

Market Cap as of 06/20/2011

$99,467,980

Market Cap as of 01/06/2011

$63,863,860

Exchange and Ticker Symbol

Nasdaq: APRI

Fields of Research

Engages in the research and development of pharmaceutical drugs and drug candidates based on its proprietary NexACT drug delivery technology

Major Products

Vitaros, Totect, NitroMist, Granisol, Aquoral, MycoVa, PrevOnco, RayVa, Nupen

Stocks

Company Trade Data

Stock Symbol Close Change Volume 52-Week
Chg %Chg High Low
APRI
1.94
  0.05  
+ 2.65%
61,122,000
2.71
1.66

Executives

Bassam Damaj

  • Chairman
  • Chief Executive Officer
  • President

Related News

Articles

Apricus will seek Canadian MycoVa approval in 2013

Apricus Biosciences Inc. (Nasdaq: APRI) said Monday it will ask Canadian regulators to approve its antifungal drug MycoVa in late 2013, and the company's shares rose in morning trading.

Subscribe Today!